|
|
|
| Application value of serum anti-phospholipase A2 receptor antibody in the diagnosis of membranous nephropathy |
| WANG Xi |
| Department of Nephrology, the Second People′s Hospital of Yunnan Province, Yunnan Province, Kunming 650000, China |
|
|
|
Abstract Objective To evaluate application value of serum anti-phospholipase A2 receptor antibody in the diagnosis of membranous nephropathy. Methods Fifty patients with membranous nephropathy treated with nephrology in Department of Nephrology, the Second People′s Hospital of Yunnan Province ("our hospital" for short) from July 2014 to August 2016 were selected as observation group. Fifty healthy subjects of our hospital Physical Examination Department were selected as control group. Serum anti-phospholipase A2 receptor antibody and a variety of biochemical immune indicators of the results between two groups were compared, the relationship between indicators were analyzed. Results The anti-phospholipase A2 antibody titer in observation group was higher than that in control group, TP and IgG in observation group were lower than those in control group, the differences were statistically significant (P < 0.05). There was no significant difference in IgM, IgA, C3 and C4 between two groups (P > 0.05). The diagnostic sensitivity of anti-phospholipase A2 antibody to membranous nephropathy was 58.00%, specificity was 98.00%. There was a positive correlation between anti-phospholipase A2 antibody and TP, IgG and IgA (r = －3.954, －0.483, －0.286, P < 0.05), and positively correlated with C4 (r = 0.256, P < 0.05), and IgM and C3 did not show correlation (P > 0.05). Conclusion The technique of detecting anti-phospholipase A2 antibody by ELISA is maturing. The diagnosis of membranous nephropathy by anti-phospholipase A2 antibody detection is a good research direction, and ELISA can be used for quantitative detection of anti-phospholipase A2 antibody, and the change of condition for membranous nephropathy monitoring and treatment of the effectiveness of the assessment, but also has the role of auxiliary judgment.
|
|
|
|
|
|
[1] 方玲，顾向明，周泽红，等.ELISA检测血清抗磷脂酶A2受体抗体在膜性肾病中的应用探讨[J].国际检验医学杂志，2017，38（4）：450-451，454.
[2] 蔡朕，汪蕾，朱向刚，等.膜性肾病合并甲状腺功能低下应用人血白蛋白引起急性肾损伤1例分析[J].中国临床医生杂志，2017，45（2）：116-118.
[3] 马雷雷，黄小桐，王明哲，等.PLA2R抗体在特发性膜性肾病中的临床研究进展[J].中国中西医结合肾病杂志，2017，18（1）：77-79.
[4] 闫振宇，买春阳，郝玉华.老年肾脏疾病患者活检病理特征分析[J].中国老年学杂志，2017，37（1）：169-171.
[5] 郭玉，赵宗峰，徐丹，等.M型磷脂酶A2受体和人类白细胞抗原基因单核苷酸多态性与维吾尔族特发性膜性肾病的相关性[J].中华实用诊断与治疗杂志，2017，31（1）：14-18.
[6] 刘莎莎，桑晓红，刘珍.特发性膜性肾病诊断及治疗研究进展[J].中华实用诊断与治疗杂志，2017，31（1）：82-84.
[7] 张晓丹，邓跃毅.中医医家辨治膜性肾病经验探析[J].现代中西医结合杂志，2017，26（1）：112-114.
[8] 彭素英，王玉洁，何宇，等.阳离子化牛血清白蛋白膜性肾病大鼠模型的建立与鉴定[J].山东医药，2016，56（48）：36-38.
[9] 高山林，李晓东，丁新国，等.小剂量多靶点免疫抑制治疗中老年特发性膜性肾病的有效性及安全性研究[J].重庆医学，2016，45（36）：5151-5153.
[10] 谢泉琨，党勇.火把花根片联合厄贝沙坦治疗特发性膜性肾病中度蛋白尿的疗效观察[J].中国中西医结合肾病杂志，2016，17（12）：1070-1071.
[11] 申嫒文，林鹭，郁胜强.IgG4升高的肾病：IgG4相关性肾病与特发性膜性肾病的研究进展[J].中国全科医学，2016，19（36）：4537-4540.
[12] 席小红，李国芬，李新.血清PLA2R抗体与膜性肾病患者病情的相关性[J].中国现代医学杂志，2016，26（4）：67-70.
[13] 伍小香，文思，朱雪婧，等.肾组织磷脂酶A2受体和血清抗磷脂酶A2受体抗体在膜性肾病中的诊断价值[J].中南大学学报：医学版，2017，42（4）：395-399.
[14] 付冉婕，李绍梅，焦素敏，等.肾组织M型磷脂酶A2受体和血清抗体在成人特发性膜性肾病的诊断价值[J].中国医师杂志，2016，18（12）：1820-1824，1828.
[15] 杨书光，窦艳娜，王春燕，等.M型磷脂酶A2受体相关检测在成人特发性膜性肾病诊断中的应用[J].中国现代医学杂志，2017，27（5）：42-46.
[16] 张丽丽，王祥，范小丽，等.成人特发性膜性肾病血清抗M型磷脂酶A2受体抗体与病情的相关性研究[J].中国现代医学杂志，2016，26（9）：44-48.
[17] 齐向明，江肖，汪燕，等.检测血清抗PLA2受体抗体在特发性膜性肾病中的意义[J].安徽医学，2016，37（8）：1005-1007.
[18] 董云，胡桂才.承德地区特发性膜性肾病与M型磷脂酶A2受体基因单核苷酸多态性的相关性研究[D].承德：承德医学院，2016.
[19] 王述莲，孙钧，郑继伟，等.抗磷脂酶A2受体抗体表达在特发性膜性肾病人肾组织及血液中的检测价值[J].实用医学杂志，2016，32（3）：434-436.
[20] 丁丽娜，陈孟华，俞敏，等.特发性膜性肾病患者肾组织PLA2R抗体联合IgG4检测的临床意义[J].宁夏医科大学学报，2015，37（11）：1256-1260，1374. |
|
|
|
